Eli Lilly (LLY) Q1 2026 Earnings Transcript

Eli Lilly delivered Q1 revenue growth of 56% and raised 2026 guidance, with full-year revenue now expected at $82 billion to $85 billion and non-GAAP EPS at $35.50 to $37.00. The company highlighted strong momentum from Zepbound and Mounjaro, with combined global revenue of $12.8 billion, plus the US FDA approval and launch of oral GLP-1 Koundeo and multiple positive Phase III readouts. Lilly also expanded its pipeline through four acquisitions and returned capital via $1.5 billion in dividends and $2.4 billion in buybacks.

Analysis

LLY’s core message is not just demand strength; it is that the company is converting category leadership into a pricing architecture that competitors will struggle to copy. The combination of high volume elasticity, expanding ex-US reimbursement, and a broader access stack means the company can keep lowering effective patient cost while preserving operating leverage, which is structurally harder for smaller obesity entrants with less manufacturing scale and weaker payer leverage. The market likely still underestimates how much of the incremental share capture is being funded by installation of a durable channel moat rather than near-term promotional spend.

The bigger second-order effect is that Koundeo shifts the obesity market from a single-product race to a segmentation game. Oral convenience, higher-acuity weight loss, add-on use, and eventually cardiometabolic-risk differentiation create multiple adoption lanes, which should expand total addressable demand faster than the sell-side’s linear model assumes. That is bad for any mono-mechanism competitor whose thesis depends on category growth being absorbed by one dominant injectable; it is also a latent positive for firms with adjacent manufacturing, digital, or specialty-channel exposure that can ride the volume wave.

The cleanest near-term risk is that management is intentionally re-accelerating investment before investors fully credit the margin durability, so the next few quarters may show noisy op-ex as a function of launch/BD cadence rather than pure earnings leverage. But the real reversal trigger would be a payer pushback cycle in 2H26: if access breadth stalls or Medicare uptake disappoints, the stock could de-rate on the assumption that price cuts are no longer converting into incremental volume. For now, the launch data and international share gains argue the opposite — that this is still an early innings volume story with pricing power embedded in the demand curve.

Consensus still seems too focused on gross margin compression and too little on the option value embedded in the pipeline breadth. If management is right that obesity is evolving into a multi-modality franchise, then the market is valuing LLY like a mature pharma winner when it may still be compounding like a platform company. That asymmetry supports staying long until there is evidence that access expansion stops translating into patient starts.

Key Decisions for Investors

• Long LLY outright into the next 1-2 quarters; risk/reward remains favorable as launch/access catalysts can re-rate the stock again before FY26 guidance proves conservative
• Pair trade: long LLY / short a less diversified obesity levered peer basket over 3-6 months; thesis is that LLY’s channel control and pipeline breadth will outgrow pure-play launch names if pricing pressure intensifies
• Buy LLY call spreads 3-6 months out to express upside from Medicare and DTC acceleration with defined downside; structure around post-Q2 and pre-DTC launch catalysts
• Watch CMS/Part D adoption closely; if channel uptake underwhelms by late summer, trim 20-30% of long exposure because the stock’s multiple is implicitly discounting smooth access expansion
• Avoid shorting LLY on margin-compression headlines alone; any drawdown on that narrative is likely a buy-the-dip setup unless payer data deteriorate materially